Skip to content
  • donation button

Blu Genes FoundationBlu Genes Foundation
  • About Us
    • c
      • About Us
      • Blu Genes Board of Directors and Committee Members
      • Blu Genes Impact Report
      • Blu Genes 2021 Annual Report
      • Blu Genes 2022/2023 Annual Report
      • Blu Genes 2024 Annual Report
  • Genetic Disorders
    • Genetic Disorders
    • Tay-Sachs Disease
    • SPG4 Cure
    • PMLD Cure
  • Research & Progress
    • SickKids-Genome Editing
    • UMass-Gene Therapy
    • Gene Therapy
  • News
    • News Updates
    • Social Media
  • Events
  • Contact Us
  • Donate
  • 0

    Cart

    No products in the cart.

  • donate

Blu Genes Foundation | NEWS UPDATE | Page 3

Girl with genetic condition in race against time | CTV News
August 23, 2021

...

An experimental gene therapy was little Alissa’s only hope. Now, instead of certain death, she faces an uncertain future.
April 30, 2021

BOSTON — Thomas Feldborg and Daria Rokina set off nearly every afternoon to explore this...

‘Her body was a prison’: How a new gene therapy changed the lives of two Canadian girls
March 21, 2021

TORONTO — A new gene therapy for an extremely rare disorder has offered two Canadian...

SickKids researchers ‘model’ future of precision medicine for rare inherited disorders
March 19, 2021

A team of researchers at The Hospital for Sick Children (SickKids) has successfully implemented a...

Coronavirus: Young Canadians with rare diseases feeling impact of pandemic
March 16, 2021

“It’s bittersweet because he’s taking a big brother role, even though he’s the little brother,”...

Sio Gene Therapies Announces First Patient Dosed in Clinical Trial of AXO-AAV-GM2 in Patients with Tay-Sachs and Sandhoff Disease (GM2 Gangliosidosis)
February 3, 2021

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2021 (GLOBE NEWSWIRE) — Sio Gene...

Taysha Gene Therapies Announces Queen’s University’s Receipt of Clinical Trial Application Approval from Health Canada for Phase 1/2 Clinical Trial of TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis
December 23, 2020

DALLAS–(BUSINESS WIRE)–Dec. 21, 2020– Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company...

Health Canada approves $2.8M treatment for spinal muscular atrophy
December 17, 2020

Health Canada has approved Zolgensma, which is bringing renewed hope to Alberta families that have...

Sio Gene Therapies Announces Positive Six-Month Follow-Up Data from Low-Dose Cohort of Phase 1/2 Trial of AXO-AAV-GM1 for GM1 Gangliosidosis
December 16, 2020

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) — Sio Gene...

Ottawa baby a pioneer of gene therapy for rare disease
December 4, 2020

“We are just so blessed that we live in the right place and that Aidan...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6

Brookfield Place, 181 Bay Street - Suite 1800
Toronto, Ontario. M5J 2T9

Tel: 647-535-GENE (4363)
Email: info@blugenes.org

  • Events
  • Gene Therapy
  • Your Impact
  • About Us
  • Genetic Disorders
  • Social Media
  • Contact Us
Copyright 2025 © BLU GENES

Blu Genes Foundation Registration # 78141 1889 RR0001

  • About Us
    • c
      • About Us
      • Blu Genes Board of Directors and Committee Members
      • Blu Genes Impact Report
      • Blu Genes 2021 Annual Report
      • Blu Genes 2022/2023 Annual Report
      • Blu Genes 2024 Annual Report
  • Genetic Disorders
    • Genetic Disorders
    • Tay-Sachs Disease
    • SPG4 Cure
    • PMLD Cure
  • Research & Progress
    • SickKids-Genome Editing
    • UMass-Gene Therapy
    • Gene Therapy
  • News
    • News Updates
    • Social Media
  • Events
  • Contact Us
  • Login
  • Newsletter
  • Donate

Login

Lost your password?